Derrick focuses on the US FDA user fee programs, regulations and policy for new and generic drugs, biologics and biosimilars, advisory committee and other agency activities, as well as federal legislation and budget matters on Capitol Hill. He also hosts Pink Sheet's Pharma Regulatory Podcast. An award-winning journalist, Derrick has been a reporter for several community newspapers and a business journal. When not following FDA, Derrick is keeping close tabs on Indiana University basketball.
Latest from Derrick Gingery
Pink Sheet editors and special guest Michael McCaughan of Prevision Policy discuss Robert F. Kennedy Jr.’s first act as HHS Secretary, former FDA Commissioner Scott Gottlieb’s suggestion that industry extend the existing user fee agreement rather than negotiate a new one, and President Trump’s policies impacting FDA advisory committee schedules and staffing.
Pink Sheet reporter and editors discuss what pushed a crucial Senate Finance Committee swing vote to support Robert F. Kennedy Jr. as HHS Secretary and the FDA slowly expanding its communications with the public amid the Trump Administration freeze.
As the US FDA determines what media inquiries it can respond to, HHS is deciding whether planned actions or meetings can move forward, depending on whether they are deemed mission-critical.
CDER and CBER once again posted net employee gains, even during the quarter that included the presidential election, despite fears that many would leave rather than endure the changes to be imposed by President Trump.
Pink Sheet reporter and editors discuss Sara Brenner’s introduction as acting FDA commissioner, Robert F. Kennedy Jr.’s confirmation hearings, the Trump Administration’s plans to end telework, and postponed meetings and other issues related to the communications freeze and travel ban.
The chair of the Senate Health, Education, Labor and Pensions Committee questioned whether Kennedy could reject anti-vaccine views in the face of data affirming their safety and efficacy.